

**ABOUT THE TEST** FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT	DISEASE	Brain glioblastoma (GBM)	PHYSICIAN	ORDERING PHYSICIAN	Yeh, Yi-Chen	SPECIMEN	SPECIMEN SITE	Brain
	NAME	Huang, Chi-Teng		MEDICAL FACILITY	Taipei Veterans General Hospital		SPECIMEN ID	S111-04817A (PF22026)
	DATE OF BIRTH	02 February 1953		ADDITIONAL RECIPIENT	None		SPECIMEN TYPE	Slide Deck
	SEX	Male		MEDICAL FACILITY ID	205872		DATE OF COLLECTION	08 February 2022
	MEDICAL RECORD #	43744178		PATHOLOGIST	Not Provided		SPECIMEN RECEIVED	28 February 2022

## Biomarker Findings

**Microsatellite status** - MS-Stable  
**Tumor Mutational Burden** - 0 Muts/Mb

## Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

**EGFR** A289V, amplification

**MDM4** amplification

**PTEN** splice site 165-1G>C, I67K - subclonal<sup>†</sup>

**CDKN2A/B** p16INK4a E61\* and p14ARF G75V

**TERT** promoter -146C>T

2 Disease relevant genes with no reportable alterations: **IDH1**, **PDGFRA**

<sup>†</sup> See About the Test in appendix for details.

## Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: **EGFR amplification** (p. 4), **TERT promoter -146C>T** (p. 7)
- Targeted therapies with potential clinical benefit **approved in another tumor type**: Cetuximab (p. 8), Erlotinib (p. 8), Gefitinib (p. 9), Panitumumab (p. 9)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 10)
- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: **TERT promoter -146C>T** (p. 7)

### BIOMARKER FINDINGS

**Microsatellite status** - MS-Stable

**Tumor Mutational Burden** - 0 Muts/Mb

### GENOMIC FINDINGS

**EGFR** - A289V, amplification

7 Trials see p. 10

**MDM4** - amplification

1 Trial see p. 12

**PTEN** - splice site 165-1G>C, I67K - subclonal

10 Trials see p. 13

### THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. see Biomarker Findings section

No therapies or clinical trials. see Biomarker Findings section

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
none	Cetuximab
	Erlotinib
	Gefitinib
	Panitumumab
none	none
none	none
none	none

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

**GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS**

*For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.*

**CDKN2A/B - p16INK4a E61\* and p14ARF G75V** ..... **p. 6**    **TERT - promoter -146C>T** ..... **p. 7**

**NOTE** Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

**Sample Preparation:** 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
**Sample Analysis:** 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
**Post-Sequencing Analysis:** 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

## BIOMARKER FINDINGS

## BIOMARKER

## Microsatellite status

## RESULT

MS-Stable

### POTENTIAL TREATMENT STRATEGIES

#### — Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors<sup>1-3</sup>, including approved therapies nivolumab and pembrolizumab<sup>4</sup>. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and

experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%,  $p=0.001$ )<sup>5</sup>.

### FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples<sup>6-8</sup>. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples<sup>6</sup>, although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs<sup>9</sup>. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM<sup>6</sup>, in GBMs with a previous lower grade astrocytoma<sup>7</sup>, and in giant cell GBM compared to classic GBM<sup>8</sup>.

### FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor<sup>10</sup>. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2<sup>10-12</sup>. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers<sup>13-15</sup>. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins<sup>10,12,14-15</sup>.

## BIOMARKER

## Tumor Mutational Burden

## RESULT

0 Muts/Mb

### POTENTIAL TREATMENT STRATEGIES

#### — Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1<sup>16-18</sup>, anti-PD-1 therapies<sup>16-19</sup>, and combination nivolumab and ipilimumab<sup>20-25</sup>. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported<sup>16,26-27</sup>. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE

mutations have benefited from treatment with anti-PD-1<sup>28-29</sup> or anti-PD-L1<sup>30</sup> therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

### FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (mut/Mb), and 4.2% of cases have high TMB (>20 mut/Mb)<sup>31</sup>. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB<sup>32-33</sup>. Increased TMB has been reported to correlate with higher tumor grade in glioma<sup>34</sup> and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency

(bMMRD)<sup>28</sup>, as well as with shorter OS of patients with diffuse glioma<sup>35</sup>.

### FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma<sup>36-37</sup> and cigarette smoke in lung cancer<sup>38-39</sup>, treatment with temozolomide-based chemotherapy in glioma<sup>40-41</sup>, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes<sup>42-46</sup>, and microsatellite instability (MSI)<sup>42,45-46</sup>. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents<sup>16,26-30</sup>.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

## GENOMIC FINDINGS

## GENE

# EGFR

## ALTERATION

A289V, amplification

## TRANSCRIPT ID

NM\_005228

## CODING SEQUENCE EFFECT

866C&gt;T

## VARIANT ALLELE FREQUENCY (% VAF)

25.3%

## POTENTIAL TREATMENT STRATEGIES

### — Targeted Therapies —

For patients with non-small cell lung cancer, EGFR activating mutations may predict sensitivity to EGFR TKIs, including erlotinib<sup>47</sup>, gefitinib<sup>48</sup>, afatinib<sup>49</sup>, dacomitinib<sup>50</sup>, and osimertinib<sup>51</sup>; however, the data for patients with other tumor types are limited<sup>52-57</sup>. A case study of a patient with multiple glioblastoma (GBM) tumors, one of which harbored EGFR amplification and multiple missense mutations, reported a near-CR of the EGFR-amplified and -mutated tumor to osimertinib<sup>58</sup>. A case series of 11 patients with bithalamic gliomas with EGFR mutations suggested that treatment with EGFR inhibitors, including osimertinib, prolonged patient survival relative to other types of treatment; however, no patients attained PR or SD<sup>55</sup>. Another case series of 2 patients with osimertinib-treated bithalamic gliomas with EGFR exon 20 insertion mutations reported that one patient experienced no progression at 4 months of treatment and that another patient did not progress until after 6 months of treatment<sup>59</sup>. Clinical studies of the second-generation EGFR TKIs afatinib and dacomitinib for patients with EGFR-amplified gliomas have shown limited efficacy<sup>57,60-63</sup>; however, a small subset of patients has experienced clinical benefit<sup>57,60-61</sup>. Multiple studies have failed to find a positive association between

increased EGFR expression and clinical benefit from erlotinib or gefitinib for patients with glioblastoma<sup>64-67</sup>. There are conflicting data on the efficacy of anti-EGFR antibodies for the treatment of EGFR-amplified tumors. A meta-analysis of colorectal cancer patients treated with second-line or higher cetuximab or panitumumab observed an association between EGFR copy number gain and increased OS and PFS<sup>68</sup>. However, studies in head and neck squamous cell carcinoma and gastric cancer found either no association or a negative association between EGFR copy number gain and survival after treatment with first-line cetuximab or panitumumab in combination with chemotherapy<sup>69-70</sup>. The Phase 3 INTELLANCE trial of depatuxizumab mafodotin (ABT-414), an EGFR-targeted antibody-drug conjugate with a toxic payload, in patients with EGFR-amplified glioblastoma (GBM) was stopped for futility. Interim analysis demonstrated improved median PFS (mPFS) of ABT-414 monotherapy compared with placebo (HR=0.84); however, no OS benefit was observed (HR=1.01). Improved mPFS was also observed in patients harboring EGFRvIII (HR=0.73) but without an OS improvement (HR=0.95)<sup>71</sup>. The Phase 2 INTELLANCE trial demonstrated clinical benefit for EGFR-amplified GBM for the combination of ABT-414, temozolomide, and radiotherapy (HR=0.66, p=0.017), but there was no evidence of efficacy for ABT-414 monotherapy (HR=1.04, p=0.83)<sup>72</sup>.

## FREQUENCY & PROGNOSIS

Across several genomic studies of CNS tumors, EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas<sup>73-76</sup>. Across several genomic studies of CNS tumors, EGFR amplification has been reported in 16.9% of anaplastic astrocytomas, and 39.7% of glioblastoma multiformes (GBMs)<sup>73-76</sup>. In the glioblastoma (GBM) TCGA dataset, putative high-level amplification of EGFR has been found in 48% of cases and mutation has been found in

21% of cases<sup>74</sup>. Missense mutations in the EGFR extracellular domain have been found in 10-15% of GBMs and approximately half have a low-level amplification of the mutated allele<sup>77-78</sup>. One study detected EGFR alterations in 50% (117/232) of IDH-wildtype GBM samples analyzed, including 41% (95/232) with a co-occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event<sup>79</sup>. No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM<sup>80-81</sup>; however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM<sup>82</sup>.

## FINDING SUMMARY

EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide<sup>83</sup>. Amplification of EGFR has been associated with increased expression of EGFR mRNA and protein in several cancer types<sup>84-86</sup>. The EGFR A289V mutation, located in the extracellular domain, has been shown to be activating<sup>77</sup>. Glioblastoma cell lines harboring an EGFR A289V or A289D mutation were shown to be dependent on EGFR kinase activity<sup>78</sup>, and other mutations at this position are also likely activating. In addition, A289V is frequently associated with increased EGFR gene copy number<sup>77</sup>.

## POTENTIAL DIAGNOSTIC IMPLICATIONS

The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v2.2021)<sup>87</sup>.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

## GENOMIC FINDINGS

## GENE

# MDM4

ALTERATION  
amplification

## POTENTIAL TREATMENT STRATEGIES

### — Targeted Therapies —

Numerous small molecules targeting MDM4 or the MDM2-MDM4 complex, including nutlins, are in preclinical and clinical development<sup>88-94</sup> and have been shown to be effective against cancer cells in the presence of a wild-type p53 allele<sup>95-98</sup>. However, higher MDM4 protein expression has

been reported in Nutlin-3 non-responder chronic lymphocytic leukemia patients than in responder patients<sup>99</sup>. Additional therapeutic mechanisms that target MDM4 are also in preclinical development<sup>93-94</sup>.

### FREQUENCY & PROGNOSIS

In the TCGA dataset, amplification of MDM4 was observed in 8.5% of glioblastoma cases<sup>74</sup>. MDM4 amplification or amplification of the 1q32.1 chromosomal locus, which encompasses MDM4 and PIK3C2B, has been frequently reported, particularly in Grade 3 and 4 astrocytoma or glioblastoma multiforme (GBM) cases; one study reported MDM4 amplification in 27% (23/86) of astrocytoma samples<sup>100-105</sup>. A study also reported

MDM4 amplification in 4% (4/106) of GBMs and in 4% (1/27) of anaplastic oligodendrogliomas; MDM4 amplification was not detected in any of the 56 low-grade (Grade 1 or 2) gliomas investigated<sup>105</sup>. The association of MDM4 amplification with tumor grade in astrocytomas is unclear<sup>100-101</sup>.

### FINDING SUMMARY

MDM4 acts as a negative regulator of p53, but a fraction of MDM4 localized to the mitochondria acts in concert with p53 to promote apoptosis<sup>106</sup>. MDM4 has been reported to be amplified in cancer and therapies targeting MDM4 or MDM2 have been shown to increase levels of the tumor suppressor p53 in cancer cells<sup>98,107-109</sup>.

## GENE

# PTEN

ALTERATION  
splice site 165-1G>C, I67K - subclonal

TRANSCRIPT ID  
NM\_000314, NM\_000314

CODING SEQUENCE EFFECT  
165-1G>C, 200T>A

VARIANT ALLELE FREQUENCY (% VAF)  
12.6%, 4.8%

## POTENTIAL TREATMENT STRATEGIES

### — Targeted Therapies —

PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway<sup>110-113</sup>. Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus<sup>114-116</sup>. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors<sup>117-121</sup>, and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer<sup>122</sup>, ovarian cancer<sup>123</sup>, uterine leiomyosarcoma<sup>124</sup>, and endometrial cancer<sup>121</sup> treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity<sup>125-126</sup>.

### — Potential Resistance —

In a retrospective analysis of 66 patients with glioblastoma, tumors from nivolumab or pembrolizumab non-responders were significantly enriched for PTEN mutations<sup>26</sup>.

### FREQUENCY & PROGNOSIS

Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma<sup>82,127-133</sup>. One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed<sup>79</sup>. In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases<sup>74</sup>, while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases<sup>134</sup>. Decreased PTEN expression is associated with the higher grade GBM tumors<sup>135</sup>. Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas<sup>130,136</sup>.

### FINDING SUMMARY

PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis<sup>111</sup>. Alterations such as

seen here may disrupt PTEN function or expression<sup>132,137-177</sup>. Although alterations such as also seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

### POTENTIAL GERMLINE IMPLICATIONS

One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2021)<sup>178</sup>. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome<sup>179-180</sup>. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients<sup>179,181</sup>. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder<sup>179</sup>. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531



ORDERED TEST # ORD-1311283-01

## GENOMIC FINDINGS

## GENE

## CDKN2A/B

## ALTERATION

p16INK4a E61\* and p14ARF G75V

## TRANSCRIPT ID

NM\_000077

## CODING SEQUENCE EFFECT

181G&gt;T

## VARIANT ALLELE FREQUENCY (% VAF)

59.6%

### POTENTIAL TREATMENT STRATEGIES

#### — Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib<sup>182-185</sup>. Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment<sup>186-187</sup>, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents<sup>188-194</sup>; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors<sup>195-196</sup>, the clinical relevance of p14ARF as a predictive biomarker is not clear.

### FREQUENCY & PROGNOSIS

Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas<sup>75</sup> and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)<sup>74</sup> than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)<sup>107,197</sup>. In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM)<sup>198-200</sup>. A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF-encoding locus alone<sup>201</sup>. One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH-wildtype GBM samples analyzed<sup>79</sup>. Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples<sup>202</sup>. Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression<sup>199,203</sup>. In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas<sup>204-205</sup>.

### FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor

p15INK4b<sup>206-207</sup>. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control<sup>208-209</sup>. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition<sup>210-211</sup>. One or more alterations observed here are predicted to result in p16INK4a loss of function<sup>212-233</sup>. One or more alterations seen here have been observed in the context of cancer but have not been characterized and their effect on p14ARF function is unclear.

### POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer<sup>234</sup>. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma<sup>235-236</sup>. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases<sup>237-239</sup>. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors<sup>240-242</sup>. In the appropriate clinical context, germline testing of CDKN2A is recommended.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

**GENOMIC FINDINGS**
**GENE**

# TERT

**ALTERATION**

promoter -146C&gt;T

**TRANSCRIPT ID**

NM\_198253

**CODING SEQUENCE EFFECT**

-146C&gt;T

**VARIANT ALLELE FREQUENCY (% VAF)**

27.0%

**POTENTIAL TREATMENT STRATEGIES**
**— Targeted Therapies —**

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials<sup>243</sup>; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth<sup>244</sup>. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer

reported no improvement in PFS or OS<sup>245</sup>.

**FREQUENCY & PROGNOSIS**

TERT promoter mutations have been reported in 51-59% of gliomas<sup>246-247</sup>, most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas<sup>246-250</sup>. In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%)<sup>246,248</sup>. One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed<sup>79</sup>. TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM<sup>251</sup>. TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM<sup>246,248,251-252</sup>. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v2.2021).

**FINDING SUMMARY**

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length<sup>253</sup>. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells<sup>254-256</sup>. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)<sup>257-259</sup>, as well as tandem mutations at positions -124/-125 bp and -138/-139 bp<sup>257</sup>.

**POTENTIAL DIAGNOSTIC IMPLICATIONS**

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v2.2021)<sup>260</sup>. The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v2.2021)<sup>87</sup>.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

## Cetuximab

*Assay findings association*

### EGFR

A289V, amplification

#### AREAS OF THERAPEUTIC USE

Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information.

#### GENE ASSOCIATION

For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies<sup>68</sup>.

#### SUPPORTING DATA

A clinical trial of cetuximab with bevacizumab (an anti-VEGF monoclonal antibody) in patients with glioblastoma (GBM) did not show improved efficacy compared with bevacizumab alone<sup>261</sup>. In preclinical trials, cetuximab, matuzumab, and panitumumab were reported to be ineffective at blocking EGFR dimerization and activation in GBM cells expressing EGFR extracellular

domain mutations<sup>262</sup>. However, another study demonstrated that in patients with GBM harboring EGFR amplification but lacking expression of the EGFRvIII variant, treatment with cetuximab resulted in significantly better progression-free survival (PFS) and numerical (although not statistically significant) improvement in overall survival (OS)<sup>263</sup>. A Phase 3 trial of combined cetuximab and platinum/5-FU in patients with HNSCC demonstrated improved response compared to platinum/5-FU alone, but EGFR amplification was not shown to predict response to this treatment<sup>69</sup>. A Phase 3 study of patients with pancreatic adenocarcinoma did not report any improved outcome in patients treated with a combination of cetuximab plus gemcitabine vs gemcitabine alone<sup>264</sup>. In a Phase 1/2 trial of 36 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cetuximab in combination with doxorubicin, stable disease was reported in approximately 63% of patients<sup>265</sup>. A Phase 1 study of the combination therapy of cetuximab, erlotinib, and bevacizumab reported stable disease in 21% (7/34) of patients with non-small cell lung cancer (NSCLC)<sup>266</sup>.

## Erlotinib

*Assay findings association*

### EGFR

A289V, amplification

#### AREAS OF THERAPEUTIC USE

Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucicromab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information.

#### GENE ASSOCIATION

Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression<sup>47,267-269</sup>. For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival<sup>270-274</sup>.

#### SUPPORTING DATA

In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activation

mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma<sup>275</sup>. A patient with EGFR-mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months<sup>276</sup>. A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response<sup>64</sup>. In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer progression-free survival relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months)<sup>277</sup>. However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity<sup>278</sup>. In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in overall survival time compared with historical controls; sorafenib was found to increase erlotinib clearance<sup>279</sup>.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531



ORDERED TEST # ORD-1311283-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

## Gefitinib

*Assay findings association*

### EGFR

A289V, amplification

### AREAS OF THERAPEUTIC USE

Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information.

### GENE ASSOCIATION

Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy<sup>269,280-285</sup>, and responses have been reported for patients with EGFR-rearranged NSCLC<sup>286-287</sup>. For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival<sup>270-274</sup>. Patients with refractory advanced esophageal carcinoma and EGFR amplification derived significant overall survival benefit from gefitinib compared to placebo (HR = 0.21)<sup>270,288</sup>.

### SUPPORTING DATA

A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response<sup>64</sup>. A Phase 2 clinical study of gefitinib in patients with high-grade glioma (including GBM, anaplastic astrocytoma, and oligodendroglioma) reported 18% (5/28) disease stabilization; efficacy was not correlated with EGFR expression<sup>65</sup>. However, a Phase 1/2 clinical trial of gefitinib combined with radiotherapy in 178 patients with GBM reported no overall survival benefit of added gefitinib, and EGFR expression was found to be of no prognostic value for patients treated with gefitinib plus radiotherapy<sup>66</sup>. A Phase 2 trial of preoperative gefitinib treatment in patients with recurrent GBM reported that although EGFR phosphorylation was decreased in treated patients as compared to the control group, measurement of 12 downstream molecules revealed no significant changes<sup>67</sup>.

## Panitumumab

*Assay findings association*

### EGFR

A289V, amplification

### AREAS OF THERAPEUTIC USE

Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information.

### GENE ASSOCIATION

For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies<sup>68</sup>.

### SUPPORTING DATA

A Phase 1 trial of EnGeneIC delivery vehicle (EDV) targeting EGFR with panitumumab in combination with

doxorubicin for 14 patients with glioblastoma (GBM) reported no responses and 28% (4/14) SDs<sup>289</sup>.

Panitumumab has shown efficacy as monotherapy or in combination with chemotherapy for patients with KRAS-wildtype colorectal cancer<sup>290-292</sup> and has been investigated in a variety of other tumor types. For patients with head and neck squamous cell carcinoma (HNSCC), data are conflicting; some trials of panitumumab in various lines and with different chemotherapy combinations have shown modest benefit<sup>293-295</sup> and others have reported no benefit<sup>296-298</sup>. A Phase 3 study of chemotherapy with or without panitumumab for patients with advanced gastroesophageal cancer was terminated for futility<sup>299</sup>. Trials in a variety of tumor types have failed to show significant benefit for patients, including non-small cell lung cancer (NSCLC)<sup>300-301</sup>; biliary tract cancers, including cholangiocarcinoma<sup>302-303</sup>; and renal cell carcinoma (RCC)<sup>304</sup>.

**NOTE** Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

**CLINICAL TRIALS**
**ORDERED TEST #** ORD-1311283-01

**NOTE** Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and

should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require

medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see [clinicaltrials.gov](https://clinicaltrials.gov). Or visit <https://www.foundationmedicine.com/genomic-testing#support-services>.

**GENE**
**EGFR**
**ALTERATION**

A289V, amplification

**RATIONALE**

EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome

resistance to current agents include next-generation EGFR inhibitors and combination therapies.

**NCT03239015**
**PHASE 2**

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

**TARGETS**

EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

**LOCATIONS:** Shanghai (China)

**NCT03783403**
**PHASE 1**

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP $\alpha$ , in Subjects With Advanced Solid and Hematologic Cancers

**TARGETS**

CD20, EGFR, SIRP-alpha

**LOCATIONS:** Heidelberg (Australia), Melbourne (Australia), Edmonton (Canada), Oregon, California, Arizona, Toronto (Canada), Oklahoma, Missouri, Pennsylvania

**NCT03810872**
**PHASE 2**

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

**TARGETS**

EGFR, ERBB4, ERBB2

**LOCATIONS:** Liège (Belgium), Brussels (Belgium), Gent (Belgium)

**NCT03618667**
**PHASE 2**

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

**TARGETS**

EGFR

**LOCATIONS:** Seoul (Korea, Republic of)

**NCT04172597**
**PHASE 2**

A Study of Pozotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

**TARGETS**

EGFR, ERBB2, ERBB4

**LOCATIONS:** California

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

CLINICAL TRIALS

**NCT02800486**
**PHASE 2**

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbix) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

**TARGETS**  
EGFR

LOCATIONS: New York

**NCT02861898**
**PHASE 1/2**

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

**TARGETS**  
EGFR

LOCATIONS: New York

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

**CLINICAL TRIALS**
**GENE**
**MDM4**
**RATIONALE**

Tumors with MDM4 amplification or overexpression and wild-type p53 may be

sensitive to inhibitors of MDM-p53 interactions.

**ALTERATION**

amplification

**NCT03725436**
**PHASE 1**

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

**TARGETS**  
MDM2, MDM4

**LOCATIONS:** Texas

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

**ORDERED TEST #** ORD-1311283-01

**CLINICAL TRIALS**
**GENE**
**PTEN**
**ALTERATION**

splice site 165-1G&gt;C, 167K - subclonal

**RATIONALE**

PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors

of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.

**NCT04337463**
**PHASE NULL**

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

**TARGETS**  
mTORC1, mTORC2, PD-1

**LOCATIONS:** Chongqing (China), Chengdu (China)

**NCT02264678**
**PHASE 1/2**

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

**TARGETS**  
ATR, PARP, PD-L1

**LOCATIONS:** Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)

**NCT04740190**
**PHASE 2**

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

**TARGETS**  
PARP

**LOCATIONS:** Hong Kong (Hong Kong)

**NCT04001569**
**PHASE 1/2**

AZD8186 and Paclitaxel in Advanced Gastric Cancer

**TARGETS**  
PI3K-beta

**LOCATIONS:** Seongnam-si (Korea, Republic of)

**NCT04715620**
**PHASE 2**

Niraparib Combined With Radiotherapy in rGBM

**TARGETS**  
PARP

**LOCATIONS:** Tianjin (China)

**NCT05035745**
**PHASE 1/2**

Selinexor &amp; Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

**TARGETS**  
XPO1, PARP

**LOCATIONS:** Singapore (Singapore)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531



ORDERED TEST # ORD-1311283-01

**CLINICAL TRIALS**
**NCT03772561**
**PHASE 1**

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

**TARGETS**  
PARP, AKTs, PD-L1

**LOCATIONS:** Singapore (Singapore)

**NCT04614909**
**PHASE NULL**

Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM

**TARGETS**  
PARP

**LOCATIONS:** Arizona

**NCT04801966**
**PHASE NULL**

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

**TARGETS**  
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

**LOCATIONS:** Melbourne (Australia)

**NCT04632992**
**PHASE 2**

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

**TARGETS**  
TRKB, ALK, TRKC, ROS1, TRKA, PD-L1, ERBB2, PI3K-alpha, RET, AKTs

**LOCATIONS:** Alaska, Washington, Oregon, California, Idaho

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

**APPENDIX**
**Variants of Unknown Significance**

**NOTE** One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

**BRIP1**  
R814C

**CARD11**  
A817T

**CD79A**  
R124H

**CUL4A**  
G35R

**EGFR**  
rearrangement

**EPHB4**  
R91H

**GABRA6**  
Y63C

**MSH2**  
I169V

**ZNF217**  
P823L

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

**APPENDIX**

Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

**DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS**

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTK	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKKN1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NTSC2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOC3
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

**DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS**

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPR2S2

\*TERC is an NCRNA

\*\*Promoter region of TERT is interrogated

**ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS**

Loss of Heterozygosity (LOH) score

Microsatellite (MS) status

Tumor Mutational Burden (TMB)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531  
 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531  
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

## APPENDIX

## About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium.



## ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:  
[www.rochefoundationmedicine.com/f1cdxtech](http://www.rochefoundationmedicine.com/f1cdxtech).

## INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

## TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

## THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

### Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

### Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification - equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss - equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

## Ranking of Therapies and Clinical Trials

### Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

### Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

## NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) ([www.nccn.org](http://www.nccn.org)). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to [NCCN.org](http://NCCN.org). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

## Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

APPENDIX

About FoundationOne®CDx

- Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.
- TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation [https://www.accessdata.fda.gov/cdrh\\_docs/pdf17/P170019B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf). The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
  - The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
  - Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
  - Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine

whether the patient is a candidate for biopsy.

- Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

#### REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

#### VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

#### Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

\*Interquartile Range = 1<sup>st</sup> Quartile to 3<sup>rd</sup> Quartile

#### VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*, *RAD51C*, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

#### VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531



ORDERED TEST # ORD-1311283-01

APPENDIX

About FoundationOne®CDx

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

#### LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

#### NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

#### NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

#### TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

#### SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 6.0.0

The median exon coverage for this sample is 757x

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

ORDERED TEST # **ORD-1311283-01**
**APPENDIX**
**References**

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) PMID: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) PMID: 26140250
3. Lal N, et al. Oncoimmunology (2015) PMID: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) PMID: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) PMID: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) PMID: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) PMID: 17498554
9. Szybka M, et al. Clin. Neuropathol. ( ) PMID: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) PMID: 26337942
11. You JF, et al. Br. J. Cancer (2010) PMID: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) PMID: 24623249
13. Boland CR, et al. Cancer Res. (1998) PMID: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) PMID: 15528785
15. Boland CR, et al. Gastroenterology (2010) PMID: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) PMID: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) PMID: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) PMID: 31405947
19. Cristescu R, et al. Science (2018) PMID: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) PMID: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) PMID: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) PMID: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) PMID: 29731394
24. Rozeman EA, et al. Nat Med (2021) PMID: 33558721
25. Sharma P, et al. Cancer Cell (2020) PMID: 32916128
26. Zhao J, et al. Nat. Med. (2019) PMID: 30742119
27. Touat M, et al. Nature (2020) PMID: 32322066
28. Bouffet E, et al. J. Clin. Oncol. (2016) PMID: 27001570
29. Johanns TM, et al. Cancer Discov (2016) PMID: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) PMID: 30073642
31. Chalmers ZR, et al. Genome Med (2017) PMID: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) PMID: 32386112
33. Johnson A, et al. Oncologist (2017) PMID: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) PMID: 26699864
35. Wang L, et al. BMC Cancer (2020) PMID: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) PMID: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) PMID: 23875803
38. Pfeifer GP, et al. Oncogene (2002) PMID: 12379884
39. Rizvi NA, et al. Science (2015) PMID: 25765070
40. Johnson BE, et al. Science (2014) PMID: 24336570
41. Choi S, et al. Neuro-oncology (2018) PMID: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) PMID: 23636398
43. Briggs S, et al. J. Pathol. (2013) PMID: 23447401
44. Heitz E, et al. Curr. Opin. Genet. Dev. (2014) PMID: 24583393
45. Nature (2012) PMID: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) PMID: 25568919
47. Rosell R, et al. Lancet Oncol. (2012) PMID: 22285168
48. Douillard JY, et al. Br. J. Cancer (2014) PMID: 24263064
49. Sequist LV, et al. J. Clin. Oncol. (2013) PMID: 23816960
50. Mok TS, et al. J. Clin. Oncol. (2018) PMID: 29864379
51. Jänne PA, et al. N. Engl. J. Med. (2015) PMID: 25923549
52. Hong MH, et al. Cancer (2020) PMID: 32749686
53. Kim HS, et al. Oncotarget (2015) PMID: 26462025
54. Kim HS, et al. Clin. Cancer Res. (2015) PMID: 25424851
55. Mondal G, et al. Acta Neuropathol (2020) PMID: 32303840
56. Cavalieri S, et al. Eur. J. Cancer (2018) PMID: 29734047
57. Chi AS, et al. JCO Precis Oncol (2020) PMID: 32923886
58. Makhlin I, et al. CNS Oncol (2019) PMID: 31769726
59. Goyal A, et al. World Neurosurg (2021) PMID: 33940677
60. Sepúlveda-Sánchez JM, et al. Neuro-oncology (2017) PMID: 28575464
61. Tanaka S, et al. Sci Rep (2019) PMID: 30644426
62. Reardon DA, et al. Neuro-oncology (2015) PMID: 25140039
63. Blumenthal DT, et al. J. Neurooncol. (2016) PMID: 27531351
64. Mellingshoff IK, et al. N. Engl. J. Med. (2005) PMID: 16282176
65. Franceschi E, et al. Br. J. Cancer (2007) PMID: 17353924
66. Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) PMID: 23182702
67. Hegi ME, et al. Mol. Cancer Ther. (2011) PMID: 21471286
68. Jiang Z, et al. PLoS ONE (2013) PMID: 23441167
69. Licitra L, et al. Ann. Oncol. (2011) PMID: 21048039
70. Smyth EC, et al. Gut (2021) PMID: 33199443
71. Lassman et al., 2019; Neuro-Oncology Abstract ACTR-21
72. Van Den Bent M, et al. Neuro Oncol (2020) PMID: 31747009
73. Jonsson P, et al. Clin. Cancer Res. (2019) PMID: 31263031
74. Brennan CW, et al. Cell (2013) PMID: 24120142
75. Ceccarelli M, et al. Cell (2016) PMID: 26824661
76. Thomas AA, et al. Neuro-oncology (2017) PMID: 28472509
77. Lee JC, et al. PLoS Med. (2006) PMID: 17177598
78. Vivanco I, et al. Cancer Discov (2012) PMID: 22588883
79. Yan et al. 2020; DOI:10.1200/PO.19.00385
80. Srividya MR, et al. J. Clin. Pathol. (2010) PMID: 20702468
81. Das P, et al. J Clin Neurosci (2011) PMID: 20888234
82. Smith JS, et al. J. Natl. Cancer Inst. (2001) PMID: 11504770
83. Ciardiello F, et al. N. Engl. J. Med. (2008) PMID: 18337605
84. Liang Z, et al. BMC Cancer (2010) PMID: 20637128
85. Bhargava R, et al. Mod. Pathol. (2005) PMID: 15920544
86. Yang YL, et al. Chin. Med. J. (2012) PMID: 22490401
87. Louis DN, et al. Neuro Oncol (2021) PMID: 34185076
88. Vaseva AV, et al. Cell Death Dis (2011) PMID: 21562588
89. Wang H, et al. Neoplasia (2011) PMID: 21750655
90. Wang H, et al. Mol. Cancer Ther. (2011) PMID: 21075910
91. Reed D, et al. J. Biol. Chem. (2010) PMID: 20080970
92. Smalley KS, et al. Cancer Res. (2007) PMID: 17210701
93. Vogel SM, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) PMID: 23035244
94. Mandke P, et al. PLoS ONE (2012) PMID: 22870278
95. Hirose M, et al. Oncoscience (2014) PMID: 25621298
96. Chang YS, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) PMID: 23946421
97. Bernal F, et al. Cancer Cell (2010) PMID: 21075307
98. Wade M, et al. Nat. Rev. Cancer (2013) PMID: 23303139
99. Bo MD, et al. Br. J. Haematol. (2010) PMID: 20507307
100. Arjona D, et al. Diagn. Mol. Pathol. (2005) PMID: 16319692
101. Schiffman JD, et al. Cancer Res. (2010) PMID: 20068183
102. Nobusawa S, et al. Brain Pathol. (2010) PMID: 20406234
103. Rao SK, et al. J. Neurooncol. (2010) PMID: 19609742
104. Jin G, et al. Neuro-oncology (2010) PMID: 20472715
105. Riemenschneider MJ, et al. Cancer Res. (1999) PMID: 10626796
106. Mancini F, et al. EMBO J. (2009) PMID: 19521340
107. Gao J, et al. Sci Signal (2013) PMID: 23550210
108. Danovi D, et al. Mol. Cell. Biol. (2004) PMID: 15199139
109. Biegging KT, et al. Nat. Rev. Cancer (2014) PMID: 24739573
110. Courtney KD, et al. J. Clin. Oncol. (2010) PMID: 20085938
111. Simpson L, et al. Exp. Cell Res. (2001) PMID: 11237521
112. Patnaik A, et al. Ann. Oncol. (2016) PMID: 27672108
113. Milella M, et al. Sci Rep (2017) PMID: 28220839
114. Galanis E, et al. J. Clin. Oncol. (2005) PMID: 15998902
115. Kreisl TN, et al. J. Neurooncol. (2009) PMID: 19018475
116. Mason WP, et al. Invest New Drugs (2012) PMID: 22160854
117. Mendes-Pereira AM, et al. EMBO Mol Med (2009) PMID: 20049735
118. Shen Y, et al. Clin. Cancer Res. (2013) PMID: 23881923
119. Chatterjee P, et al. PLoS ONE (2013) PMID: 23565244
120. McCormick A, et al. Int. J. Gynecol. Cancer (2016) PMID: 26905328
121. Forster MD, et al. Nat Rev Clin Oncol (2011) PMID: 21468130
122. Eikesdal HP, et al. Ann Oncol (2021) PMID: 33242536
123. Dougherty et al., 2014; ASCO Abstract 5536
124. Pan M, et al. Perm J (2021) PMID: 33970096
125. Sandhu SK, et al. Lancet Oncol. (2013) PMID: 23810788
126. Romero I, et al. Gynecol Oncol (2020) PMID: 32988624
127. Zhou XP, et al. Int. J. Cancer (1999) PMID: 10096247
128. Rasheed BK, et al. Cancer Res. (1997) PMID: 9331072
129. Davies MP, et al. Br. J. Cancer (1999) PMID: 10188904
130. Lin H, et al. Clin. Cancer Res. (1998) PMID: 9796977
131. Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) PMID: 10560660
132. Kato H, et al. Clin. Cancer Res. (2000) PMID: 11051241
133. Furnari FB, et al. Genes Dev. (2007) PMID: 17974913
134. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) PMID: 26061751
135. Sano T, et al. Cancer Res. (1999) PMID: 10213484
136. Srividya MR, et al. Neuropathology (2011) PMID: 21134002
137. Campbell RB, et al. J. Biol. Chem. (2003) PMID: 12857747
138. Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) PMID: 21828076
139. He X, et al. Cancer Res. (2013) PMID: 23475934
140. Han SY, et al. Cancer Res. (2000) PMID: 10866302
141. Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) PMID: 9811831
142. Pradella LM, et al. BMC Cancer (2014) PMID: 24498881
143. Kim JS, et al. Mol. Cell. Biol. (2011) PMID: 21536651
144. Denning G, et al. Oncogene (2007) PMID: 17213812
145. Hlobilkova A, et al. Anticancer Res. ( ) PMID: 16619501
146. Redfern RE, et al. Protein Sci. (2010) PMID: 20718038
147. Shenoy S, et al. PLoS ONE (2012) PMID: 22505997
148. Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) PMID: 19329485
149. Okumura K, et al. J. Biol. Chem. (2006) PMID: 16829519
150. Lee JO, et al. Cell (1999) PMID: 10555148
151. Maxwell GL, et al. Cancer Res. (1998) PMID: 9635567
152. Risinger JI, et al. Clin. Cancer Res. (1998) PMID: 9865913
153. Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531  
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531

ORDERED TEST # **ORD-1311283-01**
**APPENDIX**
**References**

- pmid: 22891331
154. Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114
  155. Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929
  156. Liu J, et al. Oncogene (2014) pmid: 23995781
  157. Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408
  158. De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691
  159. Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603
  160. Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030
  161. Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806
  162. Gil A, et al. PLoS ONE (2015) pmid: 25875300
  163. Furnari FB, et al. Cancer Res. (1998) pmid: 9823298
  164. Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629
  165. Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633
  166. Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496
  167. Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903
  168. Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158
  169. Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583
  170. Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208
  171. Nguyen HN, et al. Oncogene (2014) pmid: 24292679
  172. Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656
  173. Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147
  174. Wang X, et al. Biochem. J. (2008) pmid: 18498243
  175. Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562
  176. Nguyen HN, et al. Oncogene (2015) pmid: 25263454
  177. Shan L, et al. Cell Discov (2020) pmid: 32704382
  178. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
  179. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
  180. Orloff MS, et al. Oncogene (2008) pmid: 18794875
  181. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
  182. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
  183. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
  184. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
  185. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
  186. Elvin JA, et al. Oncologist (2017) pmid: 28283584
  187. Gao J, et al. Curr Oncol (2015) pmid: 26715889
  188. Gopalan et al., 2014; ASCO Abstract 8077
  189. Peguero et al., 2016; ASCO Abstract 2528
  190. Konecny et al., 2016; ASCO Abstract 5557
  191. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
  192. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
  193. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
  194. Johnson DB, et al. Oncologist (2014) pmid: 24797823
  195. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
  196. Gamble LD, et al. Oncogene (2012) pmid: 21725357
  197. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
  198. Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251
  199. Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337
  200. Weber RG, et al. Oncogene (2007) pmid: 16909113
  201. Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791
  202. Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817
  203. Feng J, et al. Cancer (2012) pmid: 21713760
  204. Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552
  205. Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312
  206. Quelle DE, et al. Cell (1995) pmid: 8521522
  207. Mutat. Res. (2005) pmid: 15878778
  208. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
  209. Oncogene (1999) pmid: 10498883
  210. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
  211. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
  212. Ruas M, et al. Oncogene (1999) pmid: 10498896
  213. Jones R, et al. Cancer Res. (2007) pmid: 17909018
  214. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
  215. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
  216. Rizo H, et al. J. Biol. Chem. (2001) pmid: 11518711
  217. Gombart AF, et al. Leukemia (1997) pmid: 9324288
  218. Yang R, et al. Cancer Res. (1995) pmid: 7780957
  219. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
  220. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
  221. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
  222. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
  223. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
  224. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
  225. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
  226. Koh J, et al. Nature (1995) pmid: 7777061
  227. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
  228. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
  229. Kutschner CL, et al. Physiol. Behav. (1977) pmid: 905385
  230. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
  231. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
  232. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
  233. Rutter JL, et al. Oncogene (2003) pmid: 12853981
  234. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
  235. Adv Exp Med Biol (2010) pmid: 20687502
  236. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
  237. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
  238. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
  239. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
  240. Kaufman DK, et al. Neurology (1993) pmid: 8414022
  241. Bahau M, et al. Cancer Res (1998) pmid: 9622062
  242. Chan AK, et al. Clin Neuropathol ( ) pmid: 28699883
  243. Nat Rev Clin Oncol (2017) pmid: 27245281
  244. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
  245. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
  246. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 2330248
  247. Killela PJ, et al. Oncotarget (2014) pmid: 24722048
  248. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
  249. Liu X, et al. Cell Cycle (2013) pmid: 23603989
  250. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
  251. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
  252. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
  253. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
  254. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
  255. Kim NW, et al. Science (1994) pmid: 7605428
  256. Hanahan D, et al. Cell (2000) pmid: 10647931
  257. Horn S, et al. Science (2013) pmid: 23348503
  258. Huang FW, et al. Science (2013) pmid: 23348506
  259. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
  260. Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629
  261. Hasselbalch B, et al. Neuro-oncology (2010) pmid: 20406901
  262. Gajadhar AS, et al. Mol. Cancer Res. (2012) pmid: 22232519
  263. Lv S, et al. Int. J. Oncol. (2012) pmid: 22752145
  264. Philip PA, et al. J. Clin. Oncol. (2010) pmid: 20606093
  265. Slovin SF, et al. Clin Genitourin Cancer (2009) pmid: 19815486
  266. Falchook GS, et al. Oncotarget (2013) pmid: 23435217
  267. Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771
  268. Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613
  269. Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888
  270. Petty RD, et al. J. Clin. Oncol. (2017) pmid: 28537764
  271. Philip PA, et al. J. Clin. Oncol. (2006) pmid: 16809731
  272. Xie C, et al. Br J Cancer (2020) pmid: 32958820
  273. Luo H, et al. JAMA Netw Open (2020) pmid: 33026449
  274. Lee J, et al. Lancet Oncol. (2012) pmid: 22192731
  275. Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312
  276. Nie KK, et al. Chin Med J (Engl) (2018) pmid: 29998897
  277. Prados MD, et al. J. Clin. Oncol. (2009) pmid: 19075262
  278. Kesavabhotla K, et al. J. Exp. Ther. Oncol. (2012) pmid: 22946346
  279. Peereboom DM, et al. Neuro-oncology (2013) pmid: 23328813
  280. Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314
  281. Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926
  282. Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809
  283. Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680
  284. Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826
  285. Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556
  286. Wang J, et al. Int. J. Cancer (2019) pmid: 30255937
  287. Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831
  288. Dutton SJ, et al. Lancet Oncol. (2014) pmid: 24950987
  289. Whittle JR, et al. J Clin Neurosci (2015) pmid: 26279503
  290. Douillard JY, et al. Ann. Oncol. (2014) pmid: 24718886
  291. Price TJ, et al. Lancet Oncol. (2014) pmid: 24739896
  292. Van Cutsem E, et al. J. Clin. Oncol. (2007) pmid: 17470858
  293. Vermorken JB, et al. Lancet Oncol (2013) pmid: 23746666
  294. Wirth LJ, et al. Ann. Oncol. (2010) pmid: 19892746
  295. Siano M, et al. Oncologist (2017) pmid: 28592616
  296. Mesia R, et al. Lancet Oncol (2015) pmid: 25596660
  297. Giralt J, et al. Lancet Oncol (2015) pmid: 25596659
  298. Siu LL, et al. JAMA Oncol (2016) pmid: 27930762
  299. Waddell T, et al. Lancet Oncol. (2013) pmid: 23594787
  300. Crawford J, et al. J Thorac Oncol (2013) pmid: 24389433
  301. Schuetz W, et al. Clin Lung Cancer (2015) pmid: 26094080
  302. Leone F, et al. Cancer (2016) pmid: 26540314
  303. Vogel A, et al. Eur J Cancer (2018) pmid: 29413685
  304. Rowinsky EK, et al. J. Clin. Oncol. (2004) pmid:

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

**Sample Analysis:** 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531  
**Sample Preparation:** 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531  
**Post-Sequencing Analysis:** 150 Second St., 1st Floor, Cambridge, MA 02141 | CLIA: 22D2027531

ORDERED TEST # ORD-1311283-01

APPENDIX

References

15210739

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

© 2022 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Richard Huang, M.D. | 08 March 2022  
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531  
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309  
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531  
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531